Three year outcome of the phase III clinical trials with Daclizumab

Vincenti F, Nashan B, Bumgardner G, Hardie I, Pescovitz M, Johnson RWG, Ramos E, and for the Phase III Daclizumab Study Group

American Society of Nephrology, 32nd Annual Meeting and Scientific Exposition, Miami Beach, Florida, Nov 1-8, 1999. 1999/p>

Antibodies,Monoclonal; Azathioprine; Cyclosporine; Daclizumab; Immunosuppressive Agents; Kidney Transplantation; Prednisone